Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Jun 14:1:50.
doi: 10.21037/tgh.2016.05.12. eCollection 2016.

Conversion therapy for stage IV gastric cancer-the present and future

Kazuya Yamaguchi  1 , Kazuhiro Yoshida  1 , Yoshihiro Tanaka  1 , Nobuhisa Matsuhashi  1 , Toshiyuki Tanahashi  1 , Takao Takahashi  1
Affiliations
Editorial

Conversion therapy for stage IV gastric cancer-the present and future

Kazuya Yamaguchi et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Kazuhiro Yoshida has received honoraria for lecture from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Company, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Novartis Pharma K.K., Sanofi K.K.; and research funding from Ajinomoto Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ono Pharmaceutical Co., Yakult Honsha Co., Ltd., outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The treatment strategy for the new categories of stage IV gastric cancer. A modification of the figure from reference (16).
Figure 2
Figure 2
The case presentation in category 1. Endoscopic images (A) show the primary tumor at the initial diagnosis and after 4 cycles of SOX therapy. Shrinkage of the primary tumor was obtained and part of the ulcer was scarred; CT images (B-D) show metastatic LNs at the lesser curvature and the para-aortic region. Similarly, shrinkage of the LNs was obtained, the response was considered to be a PR (76.9%), which was confirmed by the RECIST criteria.
Figure 3
Figure 3
The case presentation in category 2. CT images (A-D) show the metastatic LNs in the left (lt.) supraclavicular, lt. axillary, lesser curvature and para-aortic regions. After 7 cycles of XP/trasutuzumab therapy, the supraclavicular, axillary and para-aortic LNs had shrunk completely and a CR was confirmed.
Figure 4
Figure 4
The case presentation in category 3. An upper gastrointestinal image (A) and an endoscopic image (B) show pyloric stenosis and the thickening of the gastric wall; a CT image (C) shows bilateral hydronephrosis. After 6 cycles of S-1/DOC therapy, the patient completely recovered from hydronephrosis and oral intake became possible.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GLOBOCAN 2012 database. GLOBOCAN database. Available online: http://globocan.iarc.fr/Default.aspx
    1. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21. 10.1016/S1470-2045(08)70035-4 - DOI - PubMed
    1. Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-7. 10.1158/1078-0432.CCR-05-2425 - DOI - PubMed
    1. Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014;140:319-28. 10.1007/s00432-013-1563-5 - DOI - PMC - PubMed
    1. Tanabe K, Suzuki T, Tokumoto N, et al. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol 2010;8:40. 10.1186/1477-7819-8-40 - DOI - PMC - PubMed

Publication types

LinkOut - more resources